Compare Kimberly Clark Corp (KMB) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Philip Morris International Inc. — how do they compare? Kimberly Clark Corp trades at $97.59 (market cap $32.51B), while Philip Morris International Inc. trades at $201.19 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 9.6× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (5.24%). Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Philip Morris International Inc. for 85 Days on average.
| KMB | PM | |
|---|---|---|
Market Cap | $32.51B | $312.50B |
Volume | 6,139,913 | 5,517,172 |
Sector | Consumer Staples | Consumer Staples |
52-Week High | $121.44 | $201.19 |
52-Week Low | $93.05 | $144.33 |
Typical Hold Time | 93 Days | 85 Days |
Enterprise Value | $38.07B | $355.62B |
Dividend Yield | 5.24% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.74, up 1.31% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 11.79% net margins and 129.43% ROE, though Q2 2026 earnings missed expectations. Recent news highlights executive transitions and the pending Kenvue acquisition, while dividend sustainability questions emerge amid cash flow pressures. Analyst consensus remains cautious with 61% hold ratings despite a $117.25 price target suggesting 20% upside.
KMB presents a value opportunity with attractive dividend yield near 5%, but faces integration risks from the Kenvue deal and cash flow challenges. The stock's current discount to analyst targets offers potential upside if execution improves, though investors should monitor dividend coverage and acquisition integration closely given the bearish technical trend and mixed earnings performance.
Philip Morris International (PM) trades at $200.5, up 4.05% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, and revenue growth is robust, driven by smoke-free products like IQOS and ZYN. The stock is near its pivot point of $200, with support at $197 and resistance at $203. Cash flow trends show improving operational performance, though debt levels remain elevated.
The outlook is positive due to earnings momentum and smoke-free product expansion, but risks include regulatory pressures and high valuation. Wall Street consensus is bullish with a $212.17 price target, suggesting upside potential. Investors should weigh growth prospects against macroeconomic and industry-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
